AP NEWS
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue

November 27, 2019

NORTH CHICAGO, Ill., Nov. 27, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 25, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,862,394 shares of common stock with a par value of $0.01 per share. AbbVie’s common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV. The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on November 25, 2019, there were outstanding 6,770,092 options to purchase shares of common stock (the “Stock Options”), 7,858,656 restricted stock units (the “Restricted Stock Units”) and 2,410,155 performance shares (the “Performance Shares”). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content: http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300965891.html

SOURCE AbbVie